1 Liver Chemistries in Patients with Severe or Non-severe 2 COVID-19: A Meta-Analysis

3

4 **Short title:** Liver Chemistries in COVID-19

5

6 Xuan Dong^{1,2*}, Dan-Yi Zeng^{2*}, Yan-Yan Cai^{1*}, Wei-Ming Chen², Qing-Qing Xing¹,
7 Yan-Dan Ren³, Mei-Zhu Hong^{4†}, and Jin-Shui Pan^{1,2†}

8

9 ¹Liver Research Center, the First Affiliated Hospital of Fujian Medical University,
10 Fuzhou, Fujian, China;

11 ²School of Medicine, Xiamen University, Xiamen, Fujian, China;

12 ³Department of Gastroenterology, Zhongshan Hospital Affiliated to Xiamen
13 University, Xiamen, Fujian, China;

14 ⁴Department of Traditional Chinese Medicine, Zhongshan Hospital Affiliated to
15 Xiamen University, Xiamen, Fujian, China

16

17 **E-mails:**

18 Xuan Dong 362485659@qq.com

19 Dan-Yi Zeng 1184359451@qq.com

20 Yan-Yan Cai 474349346@qq.com

21 Wei-Ming Chen 345173327@qq.com

22 Qing-Qing Xing 582398903@qq.com

23 Yan-Dan Ren 916659998@qq.com

24 Mei-Zhu Hong 546777397@qq.com

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Liver Chemistries in Patients with COVID-19

25 Jin-Shui Pan j.s.pan76@gmail.com

26

27 *These authors contributed equally to this work.

28

29 **†Correspondence:**

30 Jin-Shui Pan, MD, PhD

31 Liver Research Center

32 the First Affiliated Hospital of Fujian Medical University

33 No. 20 Chazhong Road,

34 Fuzhou 350001, Fujian, China.

35 E-mail: j.s.pan76@gmail.com

36

37 Mei-Zhu Hong, MD

38 Department of Traditional Chinese Medicine

39 Zhongshan Hospital Affiliated to Xiamen University

40 201 Hu-Bin Nan Road

41 Xiamen, Fujian 361004, China

42 E-mail: 546777397@qq.com

43 Tel: +86-592-229-2015

44

45 **Word count:** 2555

46 **Word count of abstract:** 239

47 **Number of tables:** 1; **Number of figures:** 5

48 **Number of supplementary figures:** 5

ABSTRACT

Background and Aims: Cumulating observations have indicated that patients with coronavirus disease (COVID-19) undergo different patterns of liver impairment. We performed a meta-analysis of published liver manifestations and described the liver damage in COVID-19.

Methods: We searched PubMed, Google Scholar, Embase, Cochrane Library, medRxiv, bioRxiv, and three Chinese electronic databases through April 18, 2020, in accordance with the Preferred Reporting Items for Meta-Analyses. We analyzed pooled data on liver chemistries stratified by COVID-19 severity using a fixed or random-effects model.

Results: In the meta-analysis of 37 studies, which included a total of 6,235 patients, the pooled mean alanine aminotransferase (ALT) was 36.4 IU/L in the severe COVID-19 cases and 27.8 IU/L in the non-severe cases (95% confidence interval [CI]: -9.4 to -5.1, $p < 0.0001$). The pooled mean aspartate aminotransferase (AST) was 46.8 IU/L in the severe cases and 30.4 IU/L in the non-severe cases (95% CI: -15.1 to -10.4, $p < 0.0001$). Furthermore, regardless of disease severity, the AST level is often higher than the ALT level. Compared with the non-severe cases, the severe cases tended to have higher γ -glutamyltransferase levels but lower albumin levels.

Conclusions: In this meta-analysis, we comprehensively described three patterns of liver impairment related to COVID-19, namely hepatocellular injury, cholestasis, and hepatocellular dysfunction, according to COVID-19 severity. Patients with abnormal liver test results are at higher risk of progression to severe disease. Close monitoring of liver chemistries provides an early warning against disease progression.

KEYWORDS: PRISMA, COVID-19, SARS-CoV-2, Meta-analysis

74 **Lay Summary**

75 Data on abnormal liver chemistries related to coronavirus disease (COVID-19) are
76 cumulating but are potentially confusing. We performed a meta-analysis of 37 studies
77 that included a total of 6,235 patients with COVID-19. We noted that patients with
78 abnormal liver test results are at higher risk of progression to severe disease and close
79 monitoring of liver chemistries provides early warning against disease progression.

80

INTRODUCTION

According to the situation report released by the World Health Organization (WHO), as of April 18, 2020, 2,160,207 coronavirus disease (COVID-19) cases were confirmed globally, of which 146,088 led to deaths [1]. Although effectively controlled in mainland China, the spread and upward trend of COVID-19 have accelerated dramatically worldwide. In response to the emerging threat posed by COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the WHO has declared a Public Health Emergency of International Concern on January 30, 2020, which was further labeled as a pandemic on March 11, 2020. Similarly, the other two previously identified coronaviruses, namely SARS-CoV and Middle East Respiratory Syndrome-CoV, SARS-CoV-2 causes severe viral pneumonia in humans. As no specific acquired immunity exists in the general population, SARS-CoV-2 has high infectivity, which has resulted in an ongoing global health crisis.

Apart from the respiratory system, the urinary system, gastrointestinal tract, and even the central nervous system are the probable target organs of SARS-CoV-2, which utilizes the angiotensin-converting enzyme 2 (ACE2) receptors of the respiratory and gastrointestinal tracts as the entry point for epithelial cells [2]. Among patients' common complaints related to COVID-19 are gastrointestinal symptoms, including nausea/vomiting, diarrhea, and abdominal pain [3-6]. Abundant ACE2 protein expression in the glandular cells of gastric, duodenal, and rectal epithelia supports the entry of SARS-CoV-2 into the host epithelial cells [7]. Single-cell RNA sequencing has revealed a specific ACE2 expression in cholangiocytes [8]. Thus, performing liver chemistry tests for a number of patients with COVID-19 seems reasonable. In fact, several studies have found liver injury in patients with COVID-19 [9-13].

Liver Chemistries in Patients with COVID-19

Furthermore, cumulating observations have indicated that different patterns of abnormal liver chemistries exist between patients with severe and non-severe COVID-19. Although liver manifestations of COVID-19 pose an important diagnostic challenge to clinicians when treating patients with symptoms related to COVID-19 on initial presentation, these are potentially useful for recognizing severe cases of COVID-19 in the early stage.

Considering the diverse clinical manifestations and increasing number of reported COVID-19 cases, a systematic summary of the liver manifestations of COVID-19 is urgently needed.

Liver chemistries generally consist of hepatocellular injury-related indexes, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST); cholestatic injury-related indexes, comprised of alkaline phosphatase (AKP) and γ -glutamyltransferase (GGT); and hepatocellular function-related indexes such as albumin (ALB) level and prothrombin time (PT)^[14]. In general, total bilirubin (TBIL), direct bilirubin (DBIL), and globulin (GLB) levels, and international standardized ratio (INR) are also assessed in clinical practice. However, observations to comprehensively analyze liver chemistries in patients with COVID-19 patients are rather few. Hence, the aim of this study was to provide a comprehensive view of liver test parameters in patients with severe and non-severe COVID-19. With better knowledge, more targeted therapies and holistic care approaches could be developed.

METHODS

Studies selection

The following databases were searched from December 1, 2019, through April 18, 2020: PubMed, Google Scholar, Embase, Cochrane Library, medRxiv, bioRxiv, and three Chinese electronic databases (CQVIP, Wanfang Data, and Chinese National Knowledge Infrastructure). “Coronavirus,” “COVID-19,” “2019-nCoV-2,” “SARS-CoV-2,” or novel coronavirus were used as search keywords. Potential studies were retrieved in accordance with the PRISMA guideline [15]. Details of the database search are listed in the Supplementary file. The retrieved articles were imported to Endnote X9.3 (Thompson and Reuters, Philadelphia, Pennsylvania), and duplicates were removed.

Selection criteria

The eligibility of the potential studies was determined independently by two authors (XD and WMC), and dissonance was arbitrated by the third author (JSP). The inclusion criteria were as follows: (1) study population: adult COVID-19 patients; (2) study design: case series, case report, prospective cohort study, retrospective cohort study, case-control study, and randomized controlled trial; and (3) language: studies published in English or Chinese. The exclusion criteria were as follows: (1) pediatric patients or pregnant women; (2) patients without nucleic acid data or serology evidence of SARS-CoV2 infection; (3) asymptomatic patients with SARS-CoV2 infection; (3) study design: review article, meta-analysis, editorial, or commentary. Studies that only reported the percentages of the indexes related to liver chemistries rather than the mean or median values of the corresponding indexes were also excluded.

Data extraction

For the eligible articles, we recorded the following items: first author, study location, sample size, patient age and sex, and liver chemistry-related indexes such as ALT, AST, TBIL, DBIL, GGT, AKP, and ALB levels. The severity of COVID-19 was also recorded.

Data analysis

The statistical analyses were performed using the R version 3.2.3 statistical software (R Foundation for Statistical Computing). The continuous variables that showed a normal distribution were expressed as mean $\pm$ SD, while those that conformed to a skewed distribution were expressed as median (interquartile range [IQR]). For the studies that provided summary data of median, minimum, and maximum values, we used the method developed by Luo et al [16] to estimate the sample mean and SD for the continuous outcomes. The online tool used is provided at <http://www.math.hkbu.edu.hk/~tongt/papers/median2mean.html>. The 95% confidence interval (CI) was presented as a Forest plot. The Cochran Q test was used to detect the heterogeneity among studies, with a p value of <0.10 indicating significant heterogeneity. The I^2 statistics was calculated to measure the proportion of total variation among the studies to which the heterogeneity was attributed. I^2 values of $<25\%$, $25\text{--}75\%$, and $>75\%$ represent low, moderate, and high heterogeneity, respectively [17]. Publication bias was evaluated using a funnel plot. A subgroup analysis was performed according to disease severity.

RESULTS

Characteristics of the studies included in the meta-analysis

The selection process of the potential studies is depicted in Figure 1. Of the 2,127 studies identified, 37 studies were included in the meta-analysis. The characteristics of the enrolled studies are listed in Table 1 [9, 12, 13, 18-51]. Information, including the study location, sample size, patient age and sex, disease severity, INR, PT, and TBIL, DBIL, ALT, AST, GGT, AKP, ALB, and GLB levels, was recorded. The mean ages of patients with non-severe and severe COVID-19 were 51.1 and 64.0 years, respectively (Supplementary Figure 1). In the enrolled studies, male patients accounted for 54.6%. Among the studies that reported disease severity, severe disease accounted for 30.3% (range, 8.0–54.8%) of the cases.

Hepatocellular injury-related abnormalities in liver chemistries

Of the enrolled studies, 37 reported assays of ALT or AST in a total of 6,235 patients with COVID-19. All but one of these studies were from China. Of the 36 enrolled studies from China, 16 (44.4%) were from Hubei Province, where Wuhan is located. The pooled mean ALT level was 36.4 IU/L in the patients with severe COVID-19 and 27.8 IU/L in the patients with non-severe COVID-19 (95% CI: -9.4 to -5.1, $p < 0.0001$; Figure 2A), with significant heterogeneity among the studies ($I^2 = 69\%$, $p < 0.01$). Similarly, the pooled mean AST level was 46.8 IU/L in the severe cases and 30.4 IU/L in the non-severe cases (95% CI: -15.1 to -10.4, $p < 0.0001$; Figure 2B). Significant heterogeneity was observed for the AST levels among the studies ($I^2 = 68\%$, $p < 0.01$), which was slightly lower than that of the ALT levels ($I^2 = 69\%$, $p < 0.01$). Potential publication bias was evaluated using a funnel plot (Supplementary Figure 2). In the patients with COVID-19, the mean AST level tended to be higher

than the mean ALT level in both the severe and non-severe groups. Moreover, the gap between the AST and ALT levels (46.8 and 36.5 IU/L, respectively) was even more significant in the severe group (Figure 3). The evaluation of the publication bias is presented in Supplementary Figure 3.

Cholestasis-related abnormalities in liver chemistries

Compared with the studies that reported ALT and AST levels, rather fewer studies focused on cholestasis-related indexes such as AKP, GGT, and DBIL levels. Of the enrolled studies for the meta-analysis, 8 reported AKP assays and 5 studies reported GGT measurements. The pooled mean AKP level was 66.2 IU/L in the patients with severe COVID-19 and 61.0 IU/L in those with non-severe COVID-19 (95% CI: -11.2 to 0.1, $p > 0.05$; Figure 4A). The pooled mean GGT level was 43.2 IU/L in the severe group and 30.7 IU/L in the non-severe group (Figure 4B). The pooled mean TBIL level in the severe group was slightly higher than that in the non-severe group. However, the mean TBIL levels in both groups remained within the normal range (Figure 4C). Even fewer studies reported DBIL values in patients with COVID-19. In fact, no significant difference in mean DBIL level was found between the 2 groups (Figure 4D). For the TBIL levels, low heterogeneity was observed among the studies ($I^2 = 14\%$, $p = 0.26$). A funnel plot for the TBIL levels is shown in Supplementary Figure 4.

Hepatocellular function-related abnormalities in liver chemistries

Sixteen studies compared the mean ALB levels according to COVID-19 severity, between 713 and 1,772 severe and non-severe cases, respectively (Figure 5A). A significant heterogeneity was observed among the studies ($I^2 = 61\%$, $p < 0.01$). The mean ALB level in the patients with severe disease was significantly lower than that

Liver Chemistries in Patients with COVID-19

222 in the patients with non-severe disease. No significant difference in GLB level was
 223 found between the groups ($p = 0.17$; Figure 5B). However, in the coagulation-related
 224 indexes such as PT and INR, no significant differences were found between the
 225 severity groups. The patients in the severe group tended to have longer PT or higher
 226 INR (Figure 5C, 5D). An evaluation of publication bias in relation to ALB level and
 227 PT is shown in Supplementary Figure 5.

228

DISCUSSION

In this meta-analysis, 37 studies that consisted a total of 6,235 patients with COVID-19 from China and the United States were enrolled. According to the pooled analysis, three patterns of liver impairment, namely hepatocellular injury, cholestasis, and hepatocellular dysfunction, can develop in a proportion of patients with COVID-19 at variable severity. In brief, the patients with severe COVID-19 tended to have higher ALT/AST, AKP/GGT, and TBIL levels; higher INR; and prolonged PT. However, the severe cases had lower ALB levels than the non-severe cases. The patients with COVID-19 often had higher AST levels than ALT levels, especially in severe cases. We also observed a tendency of the severe cases to arise in the elderly. Although the liver may act as the latent target of SARS-CoV-2, the actual prevalence of abnormal liver chemistries could be underestimated because many studies did not report cholestasis-related indexes such as AKP and GGT levels, and synthetic function-related indexes such as ALB level and INR. Moreover, most studies reported ALT/AST levels on the day of admission but not throughout the disease course. This issue further compromises the role of liver chemistries in disease monitoring and provides an early warning against severe cases. As SARS-CoV-2 can lead to bile duct damage by conquering the ACE2 expressed on cholangiocytes and induce a subsequent cholestatic liver injury [8], cholestasis-related abnormalities could be overlooked. Cumulating studies have linked abnormal liver chemistries to the severity of COVID-19 [9, 19, 25]. Patients with abnormal liver test results are at higher risk of progression to severe disease [9]. In fact, coronavirus infection can cause direct damage to liver cells [11]. Moreover, several underlying diseases, comorbidities, and complications that develop in the course of the disease, such as sepsis and multiple-

Liver Chemistries in Patients with COVID-19

organ failure, and drugs that can cause potential liver damage also increase the risk of liver injury. Lopinavir/ritonavir use during hospitalization has been reported to possible lead to liver damage [9, 52]. The liver chemistry tests in the enrolled studies were all performed on admission, which suggests that the influences of the drugs on the liver tests, if any, should be minor.

ALB level and PT are known to reflect hepatocellular function. Albumin, which has a circulating half-life of 3 weeks, is a plasma protein exclusively synthesized by the liver [53]. Hypoalbuminemia results from and reflects the inflammatory state, which leads to inflammatory exudate. Effective nutrition support helps to correct hypoalbuminemia [54]. Our meta-analysis revealed that ALB level was lower in the severe cases than in the non-severe cases, which indicated that the severe cases tended to have more intense inflammation and require more solid nutrition support. PT is a far more sensitive measure of hepatocellular function than ALB level because PT may be prolonged in patients with severe liver disease duration of <24 h [14]. In accordance with the alteration of the ALB level, PT was prolonged in the severe cases, which further indicated impairment of hepatocellular function in the severe cases [53].

According to our meta-analysis, another interesting feature of liver impairment related to COVID-19 is that the AST level often overrides the ALT level, especially in severe cases. By contrast, in patients with chronic hepatitis B or nonalcoholic fatty liver disease, the ALT level is generally higher than the AST level. Although ALT is present primarily in the liver and is a more specific marker of hepatocellular injury, the distribution of AST is far wider than that of ALT, including the cardiac muscle, skeletal muscle, kidney, and brain [14]. An elevated AST level accompanied by a normal ALT level often suggests cardiac or muscle disease. In fact, cardiac injury is frequent in severe cases of COVID-19, especially in deceased patients [25, 55].

Liver Chemistries in Patients with COVID-19

279 This study has some substantial merits. First, this meta-analysis comprehensively
 280 summarized the rapidly evolving and sometimes confusing literature on COVID-19
 281 regarding the manifestation of liver chemistries. The extensive coverage of 37 studies
 282 allowed a more precise evaluation of the abnormalities of liver chemistries. Our
 283 subgroup analysis revealed that the abnormal liver chemistries were associated with a
 284 more severe disease course, highlighting the importance of a more extensive
 285 monitoring of liver chemistries for both diagnostic and prognostic purposes.
 286 Second, this analysis extensively covered all three patterns of liver impairment,
 287 namely hepatocellular injury, cholestasis, and hepatocellular dysfunction. Most
 288 observations focused on ALT, AST, and ALB levels. However, cholestasis-related
 289 impairment (e.g., abnormal AKP and GGT levels) tended to be inadvertently ignored.
 290 Moreover, we also compared hepatocellular dysfunction between the severe and non-
 291 severe cases. The alarmingly high prevalence of hypoalbuminemia in the severe cases
 292 prompts further nutrition support in severe cases. In addition, coagulation dysfunction
 293 in severe cases requires vigilance. Third, the enrolled studies included multiple
 294 observations not only from mainland China but also from other ethnic groups. This
 295 facilitates the assessment of abnormal liver chemistries related to COVID-19 in a
 296 broader ethnic context. Fourth, eligible studies preprinted in medRxiv and bioRxiv
 297 were also covered, which ensured that our analysis has a clear leading position.
 298 However, our study has a few limitations. As mentioned earlier, cholestasis-related
 299 indexes such as AKP/GGT level may be under-reported in quite a number of studies,
 300 which may lead to less precise pooled data. Second, most studies came from mainland
 301 China, which precluded a more precise estimate of the abnormalities of liver
 302 chemistries in the other ethnic groups. Most of the studies that came from mainland
 303 China seem to have an adverse impact. On the contrary, this helps to abate the

Liver Chemistries in Patients with COVID-19

304 heterogeneity caused by the disease grouping, as some potential discrepancies may
305 exist in the definition of severe and non-severe cases of COVID-19 between different
306 countries.

307

308 **CONCLUSION**

309 In this meta-analysis, we comprehensively described three patterns of liver
 310 impairment related to COVID-19, namely hepatocellular injury, cholestasis, and
 311 hepatocellular dysfunction, according to COVID-19 severity. Patients with abnormal
 312 liver test results are at higher risk of progression to severe disease. Close monitoring
 313 of liver chemistries provides an early warning against disease progression.

314

Acknowledgments

Financial support: This work was supported by the National Natural Science Foundation of China No. 81871645 (JSP). The funding source did not have any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Guarantor of the article: Professor Jin-Shui Pan

Specific author contributions: JSP and MZH were involved with the study conceptualization and design; analysis and interpretation of data; drafting of the manuscript; and approval of the final version of the manuscript; XD, DYZ, YYC, WMC, QQX, and YDR were involved in data retrieval.

Potential competing interests: None.

Table 1. Characteristics of the enrolled studies for meta-analysis

Study	Location	Number	Age [(mean±SD, or median (IQR)]	Male, number (%)	Severe, (%)	number	TBIL [(mean±SD, or median (IQR)]	DBIL [(mean±SD, or median (IQR)]	ALT [(mean±SD, or median (IQR)]	AST [(mean±SD, or median (IQR)]
Cao M ^[1]	Shanghai	198	50.1 (16.3)	101 (51.0)	19 (9.7)		8.1 (6.5–10.6)	NA	23.0 (15.0–33.0)	26.0 (20.0–34.0)
Cao W ^[2]	Hubei	128	NA	60 (46.9)	21 (16.4)		NA	NA	31.3±20.4	31.3±20.4
Chen G ^[3]	Hubei	21	56.3 (14.3)	17 (81.0)	11 (52.4)		9.8±5.6	NA	30.0±16.5	38.2±24.6
Han Y ^[4]	Hubei	47	64.9 (31.0–87.0)	26 (55.3)	24 (51.1)		15.8±10.5	NA	27.0 (17.3–49.0)	39.5±23.5
Huang C ^[5]	Hubei	41	49.0 (41.0–58.0)	30 (73.0)	13 (31.7)		11.7 (9.5–13.9)	NA	32.0 (21.0–50.0)	34.0 (26.0–48.0)
Chen X ^[6]	Hunan	291	46.0 (34.0–59.0)	145 (49.8)	50 (17.2)		10.8 (8.2–16.1)	NA	20.7 (14.9–28.9)	24.7 (19.9–31.4)
Fu L ^[7]	Anhui	350	NA	187 (53.5)	139 (39.7)		11.5±5.6	3.8±2.0	26.6±20.5	33.3±21.8
Liu L ^[8]	Chongqing	51	45.0 (34.0–51.0)	32 (62.7)	7 (13.7)		NA	NA	18.0 (14.0–30.0)	21.0 (16.0–30.0)
Wang D ^[9]	Hubei	138	56.0 (42.0–68.0)	75 (54.3)	36 (26.1)		9.8 (8.4–14.1)	NA	24.0 (16.0–40.0)	31 (24.0–51.0)
Wang Y ^[10]	Hubei	110	NA	48 (43.6)	38 (34.5)		NA	NA	NA	NA
Xie H ^[11]	Fujian	79	60.0 (48.0–66.0)	44 (55.7)	28 (35.4)		13.6 (8.8–17.6)	NA	34.0 (18.0–67.0)	30.0 (23.0–50.0)
Xu Y ^[12]	Shanghai	69	57.0 (43.0–69.0)	35 (50.7)	25 (36.2)		NA	NA	19.2 (15.1–33.1)	33.8 (26.1–47.8)

Zhao W ^[13]	Beijing	77	52.0±20.0	34 (44.2)	20 (26.0)	NA	NA	28.0 (20.0–46.0)	29.0 (21.0–42.0)
Zhang Y ^[14]	Hubei	115	49.5±17.1	49 (42.6)	31 (27.0)	11.3±5.2	NA	25.7±21.1	28.3±15.7
Zhang H ^[15]	Chongqing	43	NA	22 (51.2)	14 (32.6)	NA	NA	NA	NA
Zhang G ^[16]	Hubei	221	55.0 (39.0–66.5)	108 (48.9)	55 (24.9)	10.0 (8.0–14.2)	NA	23.0 (16.0–39.0)	29.0 (22.0–49.0)
Qu R ^[17]	Guangdong	30	50.5 (36–65)	16 (53.3)	3 (10.0)	NA	NA	NA	NA
Wu C ^[18]	Hubei	201	51.0 (43.0–60.0)	128 (63.7)	84 (41.8)	11.5 (9.0–14.8)	NA	31.0 (19.8–47.0)	33.0 (26.0–45.0)
Zheng F ^[19]	Hunan	161	45 (33.5–57.0)	80 (49.7)	30 (18.6)	10.9 (8.4–15.4)	NA	20.3 (15.0–24.5)	25.1 (19.9–32.8)
Wan S ^[20]	Chongqing	135	47 (36–55)	72 (53.3)	40 (29.6)	8.6 (5.9–13.7)	NA	26.0 (12.9–33.2)	33.4 (27.8–43.7)
Gao Y ^[21]	Anhui	43	NA	26 (60.5)	15 (34.9)	NA	NA	NA	NA
Xiang TX ^[22]	Jiangxi	49	42.9 (18–78)	33 (67.3)	9 (18.4)	8.2±3.8	2.8±1.4	22.7±12.4	27.4±12.3
Li D ^[23]	Hunan	80	47.8±19.5	40 (50.0)	17 (21.3)	NA	NA	30.0±15.6	36.2±15.4
Lu ZL ^[24]	Hubei	101	NA	34 (33.7)	34 (33.7)	NA	NA	NA	NA
Liu J ^[25]	Hubei	40	48.7±13.9	15 (37.5)	13 (32.5)	10.3±5.0	NA	22.5 (16.8–31.2)	34.1±17.7
Xiong J ^[26]	Hubei	89	53.0±16.9	41 (46.1)	31 (34.8)	NA	NA	NA	NA
Cai Q ^[27]	Guangdong	417	47.0 (34.0–60.0)	198 (47.5)	111 (26.7)	NA	NA	NA	NA
Lei S ^[28]	Hubei	34	55.0 (43.0–63.0)	14 (41.2)	15 (44.1)	9.9 (7.3–16.8)	NA	21.5 (13.0–46.3)	26.0 (20.3–55.7)

Ma J ^[29]	Hubei	37	62.0 (59.0–70.0)	20 (54.1)	20 (54.1)	NA	NA	27.0 (17.0–47.0)	24.0 (20.0–41.0)
Qian Z ^[30]	Shanghai	324	51.0 (36.0–64.0)	167 (51.5)	26 (8.0)	9.5±4.6	NA	27.9±20.0	29.3±21.0
Liu C ^[31]	Gansu	32	38.5 (26.3–45.8)	20 (62.5)	4 (12.5)	16.4 (11.3–21.1)	NA	27.0 (16.9–46.1)	24.7 (18.7–31.8)
Lu H ^[32]	Shanghai	265	NA	NA	22 (8.3)	7.9 (6.5–10.5)		23.0 (15.0–33.0)	24.0 (19.0–33.0)
Mo P ^[33]	Hubei	155	54.0 (42.0–66.0)	86 (55.5)	85 (54.8)	NA	NA	23.0 (16.0–38.0)	32.0 (24.0–48.0)
Zheng Y ^[34]	Zhejiang	34	66.0 (58.0–76.0)	23 (67.6)	15 (44.1)	12.0 (7.6–18.6)	NA	20.0 (20.0–30.0)	NA
Wang Q ^[35]	Beijing	105	45.0 (33.5–59.5)	56 (53.3)	26 (24.8)	10.2 (7.4–12.9)	NA	23.5 (14.0–36.0)	24.2 (19.7–34.8)
Shang H ^[36]	Hubei	514	54.0 (48.0–68.0)	271 (52.7)	162 (31.5)	10.8 (8.1–14.3)	3.6 (2.6–4.9)	34.0 (22.0–55.0)	33.0 (23.0–47.0)
Petrilli CM ^[37]	New York	1582	61.8±17.9	1002 (63.3)	650 (41.1)	NA	NA	36.3±22.0	47.3±26.8

Characteristics of the enrolled studies for meta-analysis (continued)

Study	Location	Number	GGT [(mean±SD, AKP or median (IQR)]	[(mean±SD, ALP or median (IQR)]	ALB [(mean±SD, or median (IQR)]	GLB [(mean±SD, PT or median (IQR)]	PT [(mean±SD, or median (IQR)]	INR [(mean±SD, or median (IQR)]
Cao M ^[1]	Shanghai	198	NA	NA	40.9 (38.0–43.1)	NA	13.3 (12.9–13.8)	NA
Cao W ^[2]	Hubei	128	NA	NA	NA	NA	NA	NA
Chen G ^[3]	Hubei	21	NA	NA	34.4±5.7	NA	13.8±1.0	NA
Han Y ^[4]	Hubei	47	NA	NA	NA	NA	12.3±1.1	NA

Huang C ^[5]	Hubei	41	NA	NA	31.4 (28.9–36.0)	NA	11.1 (10.1–12.4)	NA
Chen X ^[6]	Hunan	291	NA	NA	37.3 (34.7–40.3)	26.9 (23.8–29.6)	NA	NA
Fu L ^[7]	Anhui	350	32.2±29.2	64.9±21.8	38.7±5.5	28.6±5.4	NA	NA
Liu L ^[8]	Chongqing	51	NA	NA	40.0 (36.0–43.0)	NA	NA	NA
Wang D ^[9]	Hubei	138	NA	NA	NA	NA	13.0±1.0	NA
Wang Y ^[10]	Hubei	110	NA	NA	NA	NA	NA	NA
Xie H ^[11]	Fujian	79	31.5 (19.0–81.3)	79.0 (59.0–100.0)	NA	NA	NA	NA
Xu Y ^[12]	Shanghai	69	NA	NA	NA	NA	12.1 (11.0–13.2)	NA
Zhao W ^[13]	Beijing	77	NA	NA	NA	NA	12.7 (12.2–13.1)	NA
Zhang Y ^[14]	Hubei	115	36.1±45.0	73.7±24.4	38.8±4.4	29.2±4.0	NA	1.2±0.1
Zhang H ^[15]	Chongqing	43	NA	NA	NA	NA	NA	NA
Zhang G ^[16]	Hubei	221	NA	NA	NA	NA	12.9(12.1–13.6)	NA
Qu R ^[17]	Guangdong	30	NA	NA	NA	NA	NA	NA
Wu CM ^[18]	Hubei	201	NA	NA	32.8 (29.1–35.4)	30.7 (28.6–33.7)	11.1 (10.2–11.9)	NA
Zheng F ^[19]	Hunan	161	NA	NA	NA	NA	NA	NA

Wan S ^[20]	Chongqing	135	NA	NA	40.5 (37.0–43.4)	NA	10.9 (10.5–11.4)	NA
Gao Y ^[21]	Anhui	43	NA	NA	NA	NA	NA	NA
Xiang TX ^[22]	Jiangxi	49	NA	65.2±22.9	42.9±5.1	27.7±4.6	12.8±1.5	1.1±0.1
Li D ^[23]	Hunan	80	NA	NA	37.9±3.5	NA	13.9±1.2	NA
Lu ZL ^[24]	Hubei	101	NA	NA	NA	NA	NA	NA
Liu J ^[25]	Hubei	40	NA	NA	NA	NA	13.2±0.6	1.0±0.1
Xiong J ^[26]	Hubei	89	NA	NA	NA	NA	NA	NA
Cai Q ^[27]	Guangdong	417	NA	NA	NA	NA	NA	NA
Lei S ^[28]	Hubei	34	NA	NA	NA	NA	11.5 (10.6–12.4)	NA
Ma J ^[29]	Hubei	37	NA	NA	NA	NA	NA	NA
Qian Z ^[30]	Shanghai	324	39.0±54.4	59.9±19.0	40.6±4.1	NA	NA	1.0±0.1
Liu C ^[31]	Gansu	32	NA	NA	39.0 (36.2–44.2)	NA	NA	NA
Lu H ^[32]	Shanghai	265	NA	NA	40.8 (37.8–43.0)	NA	NA	NA
Mo P ^[33]	Hubei	155	NA	NA	38.0 (34.0–41.0)	28.0 (26.0–31.0)	NA	NA

Zheng Y ^[34]	Zhejiang	34	NA	NA	NA	NA	NA	NA
Wang Q ^[35]	Beijing	105	NA	NA	41.6 (37.9-44.7)	NA	NA	NA
Shang H ^[36]	Hubei	514	31.0 (20.0-56.0)	54.0 (43.0-71.0)	30.1 (26.8-33.9)	31.6 (28.6-35.2)	NA	NA
Petrilli CM ^[37]	New York	1582	NA	NA	NA	NA	NA	NA

327 Abbreviations: SD, standard deviation; IQR, interquartile range; TBIL, total bilirubin; DBIL, direct bilirubin; ALT, alanine aminotransferase; AST, aspartate
 328 aminotransferase; GGT, γ -Glutamyltransferase; AKP, alkaline phosphatase; ALB, albumin; GLB, globulin; PT, prothrombin time; INR, international
 329 standardized ratio; NA, not available

FIGURE LEGENDS

Figure 1. Study selection flow diagram

If all the liver chemistry indexes were not reported, these were regarded as “not available” and excluded from the meta-analysis. However, this study still enrolled studies that reported individual liver chemistry indexes if the severity of COVID-19 was reported in relation with the index.

Liver Chemistries in Patients with COVID-19

Figure 2. Forest plot of the association between serum ALT/AST level and disease severity.

Pooled levels of (A) ALT and (B) AST in the patients with COVID-19.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.

Liver Chemistries in Patients with COVID-19

Figure 3. Forest plot for the comparison of ALT and AST levels in the patients with COVID-19 stratified by disease severity

A, Forest plot for the comparison of ALT and AST levels in the non-severe cases of COVID-19. B, Forest plot for the comparison of ALT and AST levels in the severe

Liver Chemistries in Patients with COVID-19

349 cases of COVID-19.

350 Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.

351

352

Liver Chemistries in Patients with COVID-19

Figure 4. Forest plot for the association of the cholestasis-related indexes and disease severity. Pooled levels of (A) AKP, (B) GGT, (C) TBIL, and (D) DBIL in the patients with COVID-19.

Liver Chemistries in Patients with COVID-19

358 Abbreviations: AKP, alkaline phosphatase; GGT, γ -Glutamyltransferase; TBIL, total
359 bilirubin; DBIL, direct bilirubin.

360

361

Liver Chemistries in Patients with COVID-19

Figure 5. Forest plot for the association of the synthetic function-related indexes and disease severity

Pooled (A) ALB levels, (B) GLB levels, (C) PTs, and (D) INRs in the patients with COVID-19.

Liver Chemistries in Patients with COVID-19

367 Abbreviations: ALB, albumin; GLB, globulin; PT, prothrombin time; INR,

368 international standardized ratio.

369

REFERENCES

- [1] World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report–89. World Health Organization; 19 April 2020.
- [2] Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. *J Virol* 2020;94.
- [3] Cheung KS, Hung IF, Chan PP, Lung KC, Tso E, Liu R, et al. Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples from the Hong Kong Cohort and Systematic Review and Meta-analysis. *Gastroenterology* 2020.
- [4] Cholanteril G, Podboy A, Aivaliotis VI, Tarlow B, Pham EA, Spencer S, et al. High Prevalence of Concurrent Gastrointestinal Manifestations in Patients with SARS-CoV-2: Early Experience from California. *Gastroenterology* 2020.
- [5] Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. *Gut* 2020.
- [6] Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, Fang Z, et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. *Gut* 2020.
- [7] Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. *Gastroenterology* 2020.
- [8] Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A, et al. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. *bioRxiv* 2020:2020.2002.2003.931766.
- [9] Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. Characteristics of Liver Tests in COVID-19 Patients. *J Hepatol* 2020.
- [10] Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. *Lancet Gastroenterol Hepatol* 2020.

Liver Chemistries in Patients with COVID-19

- 397 [11] Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges.
398 Lancet Gastroenterol Hepatol 2020;5:428-430.
- 399 [12] Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of Non-ICU
400 hospitalized patients with coronavirus disease 2019 and liver injuryA Retrospective
401 study. Liver Int 2020.
- 402 [13] Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19
403 patients: a retrospective analysis of 115 cases from a single center in Wuhan city,
404 China. Liver Int 2020.
- 405 [14] Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal
406 Liver Chemistries. Am J Gastroenterol 2017;112:18-35.
- 407 [15] Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The
408 PRISMA statement for reporting systematic reviews and meta-analyses of studies that
409 evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
- 410 [16] Luo D, Wan X, Liu J, Tong T. How to estimate the sample mean and standard
411 deviation from the sample size, median, extremes or quartiles? Chinese Journal of
412 Evidence-Based Medicine 2017;17:1350-1356.
- 413 [17] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med
414 2002;21:1539-1558.
- 415 [18] Cao M, Zhang D, Wang Y, Lu Y, Zhu X, Li Y, et al. Clinical Features of Patients
416 Infected with the 2019 Novel Coronavirus (COVID-19) in Shanghai, China. medRxiv
417 2020:2020.2003.2004.20030395.
- 418 [19] Cao W. Clinical features and laboratory inspection of novel coronavirus pneumonia
419 (COVID-19) in Xiangyang, Hubei. 2020:2020.2002.2023.20026963.
- 420 [20] Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological
421 features of severe and moderate coronavirus disease 2019. J Clin Invest 2020.
- 422 [21] Chen X, Zheng F, Qing Y, Ding S, Yang D, Lei C, et al. Epidemiological and clinical
423 features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei, China:

Liver Chemistries in Patients with COVID-19

- 424 a double-center observational study. medRxiv 2020:2020.2003.2003.20030353.
- 425 [22] Fu L, Fei J, Xu S, Xiang HX, Xiang Y, Tan ZX, et al. Acute liver injury and its
- 426 association with death risk of patients with COVID-19: a hospital-based prospective
- 427 case-cohort study. medRxiv 2020:2020.2004.2002.20050997.
- 428 [23] Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory
- 429 data determinations for patients with the severe COVID-19. J Med Virol 2020.
- 430 [24] Han Y, Zhang H, Mu S, Wei W, Jin C, Xue Y, et al. Lactate dehydrogenase, a Risk
- 431 Factor of Severe COVID-19 Patients. 2020:2020.2003.2024.20040162.
- 432 [25] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients
- 433 infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
- 434 [26] Lei S, Jiang F, Su W, Chen C, Chen J, Mei W, et al. Clinical characteristics and
- 435 outcomes of patients undergoing surgeries during the incubation period of COVID-19
- 436 infection. EClinicalMedicine 2020:100331.
- 437 [27] Li D, Long YZ, Huang P, Guo WL, Wu SH, Zhou Q, et al. Clinical characteristics of
- 438 80 patients with COVID-19 in Zhuzhou City. Chin J Infect Control 2020;19:1-7.
- 439 [28] Liu C, Jiang ZC, Shao CX, Zhang HG, Yue HM, Chen ZH, et al. Preliminary study of
- 440 the relationship between novel coronavirus pneumonia and liver function damage: a
- 441 multicenter study. Zhonghua Gan Zang Bing Za Zhi 2020;28:148-152.
- 442 [29] Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of
- 443 lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2
- 444 infected patients. medRxiv 2020:2020.2002.2016.20023671.
- 445 [30] Liu L, Gao JY. Clinical characteristics of 51 patients discharged from hospital with
- 446 COVID-19 in Chongqing, China. medRxiv 2020:2020.2002.2020.20025536.
- 447 [31] Lu H, Ai J, Shen Y, Li Y, Li T, Zhou X, et al. A descriptive study of the impact of
- 448 diseases control and prevention on the epidemics dynamics and clinical features of
- 449 SARS-CoV-2 outbreak in Shanghai, lessons learned for metropolis epidemics
- 450 prevention. medRxiv 2020:2020.2002.2019.20025031.

Liver Chemistries in Patients with COVID-19

- 451 [32] Lu Z, He R, Jiang W, Fan T, Geng Q. Clinical characteristics and immune function
452 analysis of COVID-19. Medical Journal of Wuhan University 2020:1-5.
- 453 [33] Ma J, Yin J, Qian Y, Wu Y. Clinical Characteristics and Prognosis in Cancer Patients
454 with COVID-19: a Single Center's Retrospective Study. J Infect 2020.
- 455 [34] Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of
456 refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis 2020.
- 457 [35] Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell LF, Chernyak Y, et al.
458 Factors associated with hospitalization and critical illness among 4,103 patients with
459 COVID-19 disease in New York City. 2020:2020.2004.2008.20057794.
- 460 [36] Qi Wang HZ, Ligai Liu et al. . Characteristics and change patterns of liver function in
461 105 hospitalized adults patients with COVID-19 in Beijing, China. PREPRINT
462 (Version 1) available at Research Square 2020.
- 463 [37] Qian ZP, Mei X, Zhang YY, Zou Y, Zhang ZG, Zhu H, et al. Analysis of baseline
464 liver biochemical parameters in 324 cases with novel coronavirus pneumonia in
465 Shanghai area. Zhonghua Gan Zang Bing Za Zhi 2020;28:E005.
- 466 [38] Qu R, Ling Y, Zhang YH, Wei LY, Chen X, Li XM, et al. Platelet-to-lymphocyte
467 ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol
468 2020.
- 469 [39] Shang H, Huang C, Chen Y, Zhang S, Yang P, Hong G, et al. Digestive Involvement
470 in SARS-CoV-2 Infection: A Retrospective Multi-center Study. 2020.
- 471 [40] Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment
472 of COVID-19 patients in northeast Chongqing. J Med Virol 2020.
- 473 [41] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138
474 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan,
475 China. JAMA 2020.
- 476 [42] Wang Y, Zhou Y, Yang Z, Xia D, Geng S. Clinical Characteristics of Patients with
477 Severe Pneumonia Caused by the 2019 Novel Coronavirus in Wuhan, China.

Liver Chemistries in Patients with COVID-19

478 medRxiv 2020:2020.2003.2002.20029306.

479 [43] Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With

480 Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus

481 Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020.

482 [44] Xiang T, Liu J, Xu F, Cheng N, Liu Y, Qian K, et al. Analysis of clinical

483 characteristics of 49 patients with coronavirus disease 2019 in Jiangxi. Chinese

484 Journal of Respiratory and Critical Care Medicine 2020;19:154-160.

485 [45] Xiong J, Jiang W, Zhou Q, Hu X, Liu C. Clinical characteristics, treatment, and

486 prognosis in 89 cases of COVID-2019. Medical Journal of Wuhan University 2020:1-

487 5.

488 [46] Xu Y, Li YR, Zeng Q, Lu ZB, Li YZ, Wu W, et al. Clinical Characteristics of SARS-

489 CoV-2 Pneumonia Compared to Controls in Chinese Han Population. medRxiv

490 2020:2020.2003.2008.20031658.

491 [47] Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, et al. Clinical features and outcomes of

492 221 patients with COVID-19 in Wuhan, China. medRxiv

493 2020:2020.2003.2002.20030452.

494 [48] zhang h, wang x, fu z, luo m, zhang z, zhang k, et al. Potential Factors for Prediction

495 of Disease Severity of COVID-19 Patients. 2020:2020.2003.2020.20039818.

496 [49] Zhao W, Yu S, Zha X, Wang N, Pang Q, Li T, et al. Clinical characteristics and

497 durations of hospitalized patients with COVID-19 in Beijing: a retrospective cohort

498 study. medRxiv 2020:2020.2003.2013.20035436.

499 [50] Zheng F, Tang W, Li H, Huang YX, Xie YL, Zhou ZG. Clinical characteristics of

500 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur Rev Med

501 Pharmacol Sci 2020;24:3404-3410.

502 [51] Zheng Y, Sun L, Xu M, Pan J, Zhang Y, Fang X, et al. Clinical characteristics of 34

503 COVID-19 patients admitted to ICU in Hangzhou, China.

504 2020:2020.2004.2012.20062604.

Liver Chemistries in Patients with COVID-19

- 505 [52] Meraviglia P, Schiavini M, Castagna A, Vigano P, Bini T, Landonio S, et al.
506 Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation
507 of risk factors for liver enzyme elevation. HIV Med 2004;5:334-343.
- 508 [53] Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and
509 monitoring of hepatic injury. II. Recommendations for use of laboratory tests in
510 screening, diagnosis, and monitoring. Clin Chem 2000;46:2050-2068.
- 511 [54] Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: Pathogenesis and Clinical
512 Significance. JPEN J Parenter Enteral Nutr 2019;43:181-193.
- 513 [55] Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of
514 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ
515 2020;368:m1091.
- 516

SUPPLEMENTARY FIGURE LEGENDS

Supplementary Figure 1. Association between age and disease severity

A, Forest plot for the association of age and disease severity. B, Funnel plot for the association of age and disease severity.

Supplementary Figure 2. Funnel plot for the association of ALT/AST level and disease severity

A, Funnel plot for the association of ALT level and disease severity. B, Funnel plot for the association of AST level and disease severity.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.

Supplementary Figure 3. Funnel plot for the comparison between ALT and AST levels stratified by disease severity

A, Funnel plot for the comparison of ALT and AST levels in the non-severe cases. B, Funnel plot for the comparison between ALT and AST level in the severe cases.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.

Supplementary Figure 4. Funnel plot for the association of TBIL level and disease severity

Abbreviations: TBIL, total bilirubin.

Supplementary Figure 5. Funnel plot for the association of ALB level/PT and disease severity

A, Funnel plot for the association of ALB level and disease severity. B, Funnel plot for the association of PT and disease severity. Abbreviations: ALB, albumin; PT,

Liver Chemistries in Patients with COVID-19

542 prothrombin time.